United Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in Stock

Key Points

• United Therapeutics Director Jan Malcolm sold 700 shares of stock for a total of $280,203.00, resulting in a 57.38% decrease in their position.
• The company's stock price fell by 1.8% to $396.50, with a trading volume of 650,182 shares.
• Analysts have raised their price targets for United Therapeutics, with Jefferies Financial Group setting a new target of $564.00 and nine analysts rating the stock as a "Buy."

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Jan Malcolm sold 700 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $400.29, for a total value of $280,203.00. Following the sale, the director owned 520 shares of the company's stock, valued at $208,150.80. This trade represents a 57.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Trading Down 1.8%

Shares of United Therapeutics stock traded down $7.30 during trading hours on Wednesday, hitting $396.50. 650,182 shares of the company were exchanged, compared to its average volume of 565,346. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $436.95. The business has a 50-day moving average of $312.09 and a 200-day moving average of $306.29. The stock has a market capitalization of $17.89 billion, a price-to-earnings ratio of 15.48, a P/E/G ratio of 6.02 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the company earned $5.85 EPS. United Therapeutics's revenue for the quarter was up 11.7% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of United Therapeutics in the first quarter valued at $313,000. Allianz Asset Management GmbH increased its position in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock valued at $20,832,000 after buying an additional 33,254 shares in the last quarter. LPL Financial LLC increased its position in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock valued at $7,783,000 after buying an additional 11,007 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of United Therapeutics by 11.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after buying an additional 376 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of United Therapeutics in the first quarter valued at $227,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several research analyst reports. Jefferies Financial Group increased their price objective on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research report on Wednesday. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a research report on Thursday, September 4th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $438.85.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.